Abstract:Platinum-based chemotherapy is the most common treatment for non-small cell lung cancer (NSCLC). Expression level of drug metabolism and transport genes are correlated with platinum-based chemotherapy efficiency which indicated that variants of genes from drug metabolism and transport pathway may have an influence on chemosensitivity. In this study, we assessed whether the presence of polymorphisms in ABCB1, ABCC2 and ABCG2 genes can affect the efficacy of paclitaxel-platinum treatment in NSCLC patients. 64 NSCLC patients who received plataxel and cisplatin/carboplatin chemotherapy were involved. ABCB1 1236T > C, ABCB1 3435C > T, ABCC2 -24C > T, ABCC2 3972C > T, and ABCG2 421C > A were assessed for their association with the efficiency of paclitaxelplatinum chemotherapy. Among 5 polymorphisms assessed, ABCG2 421 A/A was associated with higher response rate (OR = 0.073; 95% CI: 0.009-0.602; P = 0.015) and ABCC2 -24C > T was found to associate with progressionfree survival (additive model: HR = 1.995; 95% CI: 1.171-3.398; P = 0.011). No association was observed between all these polymorphisms and overall survival. The results indicated that polymorphisms of the ABCG2 and ABCC2 genes might be predictive biomarkers of treatment efficiency for advanced NSCLC patients received paclitaxelplatinum treatment. This finding requires further validation.

Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer